2021: Best of DermWorld Insights and Inquiries
December 30, 2021
We know how much you enjoy Dr. Heymann and the editorial board’s weekly analyses of dermatologic literature, so we’ve created a list of the top 10 most popular issues in 2021 — starting with the most popular issue of the year.
1. Biotin supplementation for hair and nail health: Does it pass the test?
When patients ask me about biotin supplementation for their hair or nails, the usual question is what dose they should take, not whether or not it has any value. Keep reading.
2. Lipschütz ulcers: Not only for women
A few years ago, following my presentation on the cutaneous manifestations of Epstein-Barr infection, Dr. Jeffrey Callen, one of the world’s premier dermatologists, asked me “why don’t Lipschütz ulcers appear in boys?” Keep reading.
3. Playing the field: Introducing tirbanibulin for actinic keratosis therapy
Tirbanibulin’s short course of application is appealing, but its bottom line will be based on how its efficacy compares to the long-reigning champion, 5-fluorouracil. Experience has taught us that post-marketing analysis may remove AK treatments from our therapeutic options. Keep reading.
4. Putting a finger on the diagnosis of Achenbach syndrome
Castillo et al reported the case a 48-year-old woman complaining of acute pain, swelling, and ecchymosis of the volar aspect of her right third finger, sparing the fingertip, when walking her dog. Be honest — would you have diagnosed Achenbach syndrome. Keep reading.
5. Is ivermectin an old drug with new tricks?
As it stands, the use of ivermectin for the treatment of COVID-19 outside of sanctioned clinical studies is strongly discouraged. To echo the FDA’s recent tweet, “You are not a horse. You are not a cow. Seriously, y’all. Stop it.” Keep reading.
6. Going green: The complexities of the green nail syndrome
I find a unique satisfaction in diagnosing the green nail syndrome — it is easy to recognize and very reassuring to patients who were convinced they had a subungual melanoma. Based on new data, my concern is that the instantaneous diagnosis may have occasionally obviated further scrutiny of their nail disorder(s). Keep reading.
7. Humbled again: Alopecic and aseptic nodules of the scalp
I confess. I had never heard of alopecic and aseptic nodules of the scalp (AANS) and have probably beaten around the bush with alternative (incorrect) diagnoses when confronted with probable cases. Keep reading.
8. Assessing the significance of a Long-Developed Habit: The role of LDH in dermatology
Upon ordering laboratory tests recently for a patient with cutaneous T cell lymphoma, I included a lactate dehydrogenase (LDH) level, as I have done for decades, without giving it much thought. When I came across an article entitled “Lactate dehydrogenase in dermatology practice,” I asked myself, why have I been ordering an LDH? Keep reading.
9. A shot in the dark
For the past few Mondays, I have been asked to see the following “emergency” patients who called in with the diagnosis of cellulitis after the COVID-19 vaccination. Keep reading.
10. Multiple pilomatricomas by the numbers
Pilomatricomas are usually solitary lesions. When multiple (notably >6) a careful assessment is warranted to determine if there is an associated syndrome, which may not yet have become apparent. Keep reading.
As we approach nearly three years of publishing DermWorld Insights and Inquiries, you might be wondering what the most popular issue is of all time. Take a look at this reader favorite from April 2020!
All content found on Dermatology World Insights and Inquiries, including: text, images, video, audio, or other formats, were created for informational purposes only. The content represents the opinions of the authors and should not be interpreted as the official AAD position on any topic addressed. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
DW Insights and Inquiries archive
Explore hundreds of Dermatology World Insights and Inquiries articles by clinical area, specific condition, or medical journal source.
All content solely developed by the American Academy of Dermatology
The American Academy of Dermatology gratefully acknowledges the support from Bristol Myers Squibb.